Contents

Search

lorcaserin (Belviq)

FDA did not approve 2010 [2] FDA-approval recommended May 2012 [4]; FDA-approved June 2012 [5] FDA asked Eisai to voluntary withdraw lorcaserin from the U.S. markket Feb 13, 2020 due to increased risk for cancer [11] Indications: - weight reduction, obesity, marginally effective - may slow progression to type 2 diabetes & promote remission of type 2 diabetes [9] Dosage: 10 mg PO BID Adverse effects: - increased risk of cancer? [2,10] - withdrawn from U.S. markket Feb 2020 due to increased risk for cancer [11] - headache, dizziness, nausea - lowest rate of discontinuation because of adverse effects among orlistat, liraglutide, Qsymia, Contrave [7] - no overall increase in cardiovascular events [8] - nonsignificant increase valvulopathy & pulmonary hypertension [8] Mechanism of action: - selective serotonin 2C receptor agonist

Interactions

drug adverse effects of triptan(s)

General

serotonin agonist (5-HT receptor agonist, triptan)

References

  1. Smith SR et al Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management New Engl J Med 2010, 363:245-256 PMID: 20647200 http://content.nejm.org/cgi/content/short/363/3/245
  2. FDA Issues Complete Response Letter for Lorcaserin New Drug Application Arena Pharmaceuticals, October 23, 2010 http://invest.arenapharm.com/releasedetail.cfm?ReleaseID=521977
  3. No F.D.A. Approval for New Diet Pill New York Times October 23, 2010 http://topics.nytimes.com/top/reference/timestopics/people/p/andrew_pollack/index.html?inline=nyt-per
  4. Anonymous FDA advisers recommend approval of lorcaserin; could be first new weight loss drug in a decade Associated Press, May 10, 2012 http://www.washingtonpost.com/politics/fda-advisers-recommend-approval-of-lorcaserin-could-be-first-new-weight-loss-drug-in-a-decade/2012/05/10/gIQA1jVMGU_story.html - FDA Briefing Document Lorcaserin Hydrochloride Tablets, 10 mg Sponsor: Arena Pharmaceuticals Endocrinologic and Metabolic Drugs Advisory Committee Meeting, May 10, 2012 http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM303198.pdf
  5. FDA News Release: June 27, 2012 FDA approves Belviq to treat some overweight or obese adults http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309993.htm
  6. Shyh G, Cheng-Lai A. New antiobesity agents: lorcaserin (Belviq) and phentermine/ topiramate ER (Qsymia). Cardiol Rev. 2014 Jan-Feb;22(1):43-50. Review. PMID: 24304809
  7. Khera R, Murad MH, Chandar AK et al. Association of pharmacological treatments for obesity with weight loss and adverse events: A systematic review and meta-analysis. JAMA 2016 Jun 14; 315:2424 PMID: 27299618
  8. Bohula EA, Wiviott SD, McGuire DK et al. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med 2018 Aug 26; PMID: 30145941 Free Article https://www.nejm.org/doi/10.1056/NEJMoa1808721 - Ingelfinger JR, Rosen CJ. Lorcaserin - Elixir or liability? N Engl J Med 2018 Aug 26 PMID: 30145932 Free Article https://www.nejm.org/doi/10.1056/NEJMe1810855
  9. Bohula EA et al. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): A randomised, placebo-controlled trial. Lancet 2018 Oct 4; PMID: 30293771 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32328-6/fulltext - Unamuno X, Fruhbeck G. Lorcaserin: Balancing efficacy with potential risks. Lancet 2018 Oct 4 PMID: 30293772 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32460-7/fulltext
  10. FDA Safety Watch. Feb 14, 2020 Belviq, Belviq XR (lorcaserin): Drug Safety Communication - Due to Possible Increased Risk of Cancer. https://www.fda.gov/safety/medical-product-safety-information/belviq-belviq-xr-lorcaserin-drug-safety-communication-due-possible-increased-risk-cancer
  11. Otto A Lorcaserin (Belviq) Withdrawn From US Market Due to Cancer Risk. Medscape - Feb 13, 2020. https://www.medscape.com/viewarticle/925253